Paclitaxel-loaded PLGA NPs | Endocytosis | A549 lung adenocarcinoma and Lewis lung carcinoma | Intravenous injection | • Improved biodistribution in lung tumors | Layek et al., 2018 |
• Improved antitumor efficacy |
• Reduced dose dependent toxicity |
DOX-polymer conjugates | Receptor-dependent endocytosis | Intracerebral glioma | Intracranial administration | • Enhanced penetration and sustained release of doxorubicin in tumor | Zhang et al., 2015 |
• Improved survival |
Biotinylated DOX-polymer conjugates | Endocytosis and membrane anchoring via avidin-biotin complex | Metastatic pulmonary breast cancer | Intravenous injection | • Improved payload capacity | Yao et al., 2017 |
• Improved survival and tumor inhibition |
TAT-functionalized paclitaxel-loaded PLGA NPs | Cell penetrating peptide–mediated endocytosis | A549 lung adenocarcinoma | Intravenous injection | • Improved payload capacity | Moku et al., 2019 |
• Improved survival and tumor inhibition |
Plasmonic-magnetic hybrid NPs (LDGI) | Endocytosis | TNBC | Intratumoral and intravenous injection | • Enhanced migration and penetration | Xu et al., 2018 |
• Improved antitumor efficacy |
Antibody conjugated CNT/doxorubicin conjugate | Cell surface anchoring via antibody-antigen recognitions | A549 lung adenocarcinoma | Intravenous injection | • Improved survival and tumor inhibition | Kim et al., 2018 |
Antibody-conjugated doxorubicin-loaded silica nanorattles | Cell surface anchoring via antibody-antigen recognition | Glioma | Intratumoral administration | • Improved penetration and tumor kill | Li et al., 2011 |
Doxorubicin-loaded PLGA NPs | Simple endocytosis | Metastatic lung tumor | Intravenous injection | • Enhanced targeting and permeation into tumor nest | Zhao et al., 2017 |
• Significant reduction of lung metastases |